Financial reports
ARS
2023 FY
Annual report to shareholders
15 Mar 24
10-K
2023 FY
Annual report
23 Feb 24
10-Q
2023 Q3
Quarterly report
3 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
10-Q
2023 Q1
Quarterly report
4 May 23
ARS
2022 FY
Annual report to shareholders
27 Feb 23
10-K
2022 FY
Annual report
24 Feb 23
10-Q
2022 Q3
Quarterly report
3 Nov 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
10-Q
2022 Q1
Quarterly report
4 May 22
Current reports
8-K
Moderna Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Updates
22 Feb 24
8-K
Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
8 Jan 24
8-K
Departure of Directors or Certain Officers
12 Dec 23
8-K
Regulation FD Disclosure
6 Nov 23
8-K
Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates
2 Nov 23
8-K
Regulation FD Disclosure
16 Oct 23
8-K
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
11 Sep 23
8-K
Moderna Reports Second Quarter 2023 Financial Results and Provides Business Updates
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
5 May 23
8-K
Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates
4 May 23
Registration and prospectus
S-8
Registration of securities for employees
23 Feb 24
S-3ASR
Automatic shelf registration
5 May 23
424B5
Prospectus supplement for primary offering
20 May 20
S-3ASR
Automatic shelf registration
18 May 20
S-8
Registration of securities for employees
27 Feb 20
424B5
Prospectus supplement for primary offering
12 Feb 20
FWP
Free writing prospectus
10 Feb 20
FWP
Free writing prospectus
10 Feb 20
424B5
Prospectus supplement for primary offering
10 Feb 20
S-3ASR
Automatic shelf registration
10 Feb 20
Proxies
DEFA14A
Additional proxy soliciting materials
21 Mar 24
DEF 14A
Definitive proxy
21 Mar 24
PRE 14A
Preliminary proxy
11 Mar 24
DEFA14A
Additional proxy soliciting materials
14 Apr 23
PX14A6G
Letter to shareholders
13 Apr 23
DEFA14A
Additional proxy soliciting materials
15 Mar 23
DEF 14A
Definitive proxy
15 Mar 23
PX14A6G
Letter to shareholders
25 Mar 22
PX14A6G
Letter to shareholders
21 Mar 22
DEFA14A
Additional proxy soliciting materials
9 Mar 22
Other
UPLOAD
Letter from SEC
5 May 23
CORRESP
Correspondence with SEC
28 Apr 23
UPLOAD
Letter from SEC
20 Apr 23
SEC STAFF
SEC staff action: Order
16 Apr 21
SEC STAFF
SEC staff action: Order
19 Mar 21
CERT
Certification of approval for exchange listing
7 Dec 18
EFFECT
Notice of effectiveness
7 Dec 18
CT ORDER
Confidential treatment order
7 Dec 18
Ownership
4
NOUBAR AFEYAN
19 Apr 24
144
Notice of proposed sale of securities
17 Apr 24
4
Stephen Hoge
16 Apr 24
144
Notice of proposed sale of securities
15 Apr 24
4
NOUBAR AFEYAN
12 Apr 24
144
Notice of proposed sale of securities
10 Apr 24
SC 13G/A
VANGUARD GROUP INC
10 Apr 24
4
James M Mock
9 Apr 24
144
Notice of proposed sale of securities
8 Apr 24
4
NOUBAR AFEYAN
5 Apr 24